GSK Pharma Q1 PAT slips 1.5% YoY

Image
Capital Market
Last Updated : Jul 26 2022 | 10:16 AM IST

The pharmaceutical firm's consolidated net profit slipped 1.5% to Rs 119.28 crore on 3.7% increase in net sales to Rs 745.10 crore in Q1 FY23 over Q1 FY22.

Profit before tax (PBT) from continuing operations for the first quarter was Rs 160.03 crore, recording a growth of 9.5% YoY.

Total expenses rose 1.8% YoY to Rs 596.18 crore in Q1 FY23. Cost of raw materials declined 15.3% to Rs 153.78 crore in Q1 FY23 over Q1 FY22.

Sridhar Venkatesh, managing director, GlaxoSmithKline Pharmaceuticals, said, "Our results reflect good momentum across general medicines and vaccines during the quarter. We have delivered strong underlying growth with market share gains across focus brands. Our vaccines business has maintained leadership in the self-pay segment while the overall vaccines market continues to be in decline.

During the quarter, we launched one of our innovative products, Trelegy Ellipta the first single-inhaler triple therapy (SITT) in India for Chronic Obstructive Pulmonary Disease (COPD) patients in a once-daily regime for patients aged 18 and above. With this launch, we are enabling Indian COPD patients to benefit from this world-leading medicine. We expect to build on this momentum as we continue to invest in our focus brands to drive growth."

GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies.

The scrip rose 0.07% to currently trade at Rs 1,494.95 on the BSE.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 26 2022 | 9:28 AM IST

Next Story